Originally published by our sister publication Pharmacy Practice News
Meitheal Pharmaceuticals Inc., a fully integrated biopharmaceutical company based in Chicago focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced it has received FDA approval for and launched liraglutide injection (18 mg/3 mL), its generic equivalent for Victoza (Novo Nordisk) in the United States.
Liraglutide injection is a glucagon-like peptide-1 (GLP-1)